{"id":70015,"date":"2026-07-15T12:23:05","date_gmt":"2026-07-15T04:23:05","guid":{"rendered":"https:\/\/flcube.com\/?p=70015"},"modified":"2026-07-15T12:23:06","modified_gmt":"2026-07-15T04:23:06","slug":"kelun-biotechs-sacituzumab-tirumotecan-achieves-worlds-first-adc-immunotherapy-phase-iii-success-in-pd-l1-negative-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70015","title":{"rendered":"Kelun-Biotech&#8217;s Sacituzumab Tirumotecan Achieves World&#8217;s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.\u00a0(<a href=\"https:\/\/www.google.com\/finance\/quote\/6990:HKG\">HKG: 6990<\/a>)<\/strong> announced that its <strong>Phase III clinical study<\/strong> evaluating <strong>sacituzumab tirumotecan (sac-TMT)<\/strong> in combination with <strong>MSD&#8217;s pembrolizumab (Keytruda)<\/strong> has <strong>met primary endpoints<\/strong> for <strong>first-line treatment of PD-L1-negative, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)<\/strong>. This represents the <strong>world&#8217;s first Phase III success<\/strong> of an <strong>antibody-drug conjugate (ADC) combined with an immune checkpoint inhibitor<\/strong> in this challenging patient population.<\/p>\n\n\n\n<h2 id=\"h-clinical-development-milestone\" class=\"wp-block-heading\">Clinical Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Phase<\/strong><\/td><td>Phase III<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>PD-L1-negative, driver-gene-negative, non-squamous NSCLC (first-line)<\/td><\/tr><tr><td><strong>Combination Therapy<\/strong><\/td><td>Sacituzumab tirumotecan + Pembrolizumab (Keytruda)<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Met (specific endpoints not disclosed)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Locally advanced or metastatic non-squamous NSCLC<\/td><\/tr><tr><td><strong>Global Significance<\/strong><\/td><td>World&#8217;s first ADC-immunotherapy Phase III success in PD-L1-negative NSCLC<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-strategic-partnership\" class=\"wp-block-heading\">Drug Profile &amp; Strategic Partnership<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Proprietary antibody-drug conjugate (ADC) targeting TROP2 (human trophoblast cell-surface antigen 2)<\/li>\n\n\n\n<li><strong>Indications:<\/strong> Advanced solid tumors including NSCLC, breast cancer, gastric cancer, gynecological cancers, and genitourinary cancers<\/li>\n\n\n\n<li><strong>Partnership:<\/strong> MSD holds exclusive rights for development, manufacturing, and commercialization outside Greater China (since May 2022)<\/li>\n\n\n\n<li><strong>Regulatory Status:<\/strong> Marketing application previously submitted to NMPA for PD-L1-positive NSCLC indication<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-innovation-addressing-unmet-need\" class=\"wp-block-heading\">Clinical Innovation \u2013 Addressing Unmet Need<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Challenge<\/th><th>Kelun-Biotech Solution<\/th><th>Competitive Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>PD-L1-Negative NSCLC<\/strong><\/td><td>ADC-immunotherapy combination<\/td><td>First successful Phase III in this population<\/td><\/tr><tr><td><strong>Limited Treatment Options<\/strong><\/td><td>TROP2-targeted ADC + checkpoint inhibitor<\/td><td>Dual mechanism addressing tumor and immune microenvironment<\/td><\/tr><tr><td><strong>Driver-Gene Negative<\/strong><\/td><td>Novel therapeutic approach for difficult-to-treat subset<\/td><td>Expands treatable NSCLC population beyond current standards<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The breakthrough addresses a significant unmet medical need, as PD-L1-negative, driver-gene-negative NSCLC patients have historically shown limited response to immunotherapy monotherapy and represent a challenging therapeutic segment.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-commercial-strategy\" class=\"wp-block-heading\">Market Impact &amp; Commercial Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NSCLC Market Opportunity:<\/strong> PD-L1-negative NSCLC represents approximately 40-50% of non-squamous NSCLC cases globally, creating substantial commercial potential<\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> World-first data positions sacituzumab tirumotecan as a potential new standard of care in combination with pembrolizumab<\/li>\n\n\n\n<li><strong>Strategic Positioning:<\/strong> Dual regulatory pathway with NMPA applications for both PD-L1-positive and PD-L1-negative indications maximizes market coverage<\/li>\n\n\n\n<li><strong>Global Commercialization:<\/strong> MSD partnership ensures worldwide development and commercialization outside Greater China, while Kelun-Biotech retains full rights in its home market<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding sacituzumab tirumotecan&#8217;s clinical development and regulatory pathway. Actual results may differ due to risks including final data analysis, regulatory approvals, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071500036_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026071500036_c.\"><\/object><a id=\"wp-block-file--media-2fd3a5b3-0415-4ef7-b2cc-d1a415acd855\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071500036_c.pdf\">2026071500036_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071500036_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-2fd3a5b3-0415-4ef7-b2cc-d1a415acd855\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.\u00a0(HKG: 6990) announced that its Phase III clinical study evaluating sacituzumab&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[16,17,971,1832,120,2675,176],"class_list":["post-70015","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-results","tag-hkg-6990","tag-kelun-biotech-biopharmaceutical","tag-merck","tag-merck-sharp-dohme","tag-msd"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Kelun-Biotech&#039;s Sacituzumab Tirumotecan Achieves World&#039;s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.\u00a0(HKG: 6990) announced that its Phase III clinical study evaluating sacituzumab tirumotecan (sac-TMT) in combination with MSD&#039;s pembrolizumab (Keytruda) has met primary endpoints for first-line treatment of PD-L1-negative, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). This represents the world&#039;s first Phase III success of an antibody-drug conjugate (ADC) combined with an immune checkpoint inhibitor in this challenging patient population.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70015\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kelun-Biotech&#039;s Sacituzumab Tirumotecan Achieves World&#039;s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC\" \/>\n<meta property=\"og:description\" content=\"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.\u00a0(HKG: 6990) announced that its Phase III clinical study evaluating sacituzumab tirumotecan (sac-TMT) in combination with MSD&#039;s pembrolizumab (Keytruda) has met primary endpoints for first-line treatment of PD-L1-negative, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). This represents the world&#039;s first Phase III success of an antibody-drug conjugate (ADC) combined with an immune checkpoint inhibitor in this challenging patient population.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70015\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-15T04:23:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-15T04:23:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70015#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70015\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kelun-Biotech&#8217;s Sacituzumab Tirumotecan Achieves World&#8217;s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC\",\"datePublished\":\"2026-07-15T04:23:05+00:00\",\"dateModified\":\"2026-07-15T04:23:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70015\"},\"wordCount\":395,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial results\",\"HKG: 6990\",\"Kelun-Biotech Biopharmaceutical\",\"Merck\",\"Merck Sharp &amp; Dohme\",\"MSD\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70015#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70015\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70015\",\"name\":\"Kelun-Biotech's Sacituzumab Tirumotecan Achieves World's First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-15T04:23:05+00:00\",\"dateModified\":\"2026-07-15T04:23:06+00:00\",\"description\":\"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.\u00a0(HKG: 6990) announced that its Phase III clinical study evaluating sacituzumab tirumotecan (sac-TMT) in combination with MSD's pembrolizumab (Keytruda) has met primary endpoints for first-line treatment of PD-L1-negative, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). This represents the world's first Phase III success of an antibody-drug conjugate (ADC) combined with an immune checkpoint inhibitor in this challenging patient population.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70015#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70015\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70015#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kelun-Biotech&#8217;s Sacituzumab Tirumotecan Achieves World&#8217;s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kelun-Biotech's Sacituzumab Tirumotecan Achieves World's First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC - Insight, China&#039;s Pharmaceutical Industry","description":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.\u00a0(HKG: 6990) announced that its Phase III clinical study evaluating sacituzumab tirumotecan (sac-TMT) in combination with MSD's pembrolizumab (Keytruda) has met primary endpoints for first-line treatment of PD-L1-negative, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). This represents the world's first Phase III success of an antibody-drug conjugate (ADC) combined with an immune checkpoint inhibitor in this challenging patient population.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70015","og_locale":"en_US","og_type":"article","og_title":"Kelun-Biotech's Sacituzumab Tirumotecan Achieves World's First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC","og_description":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.\u00a0(HKG: 6990) announced that its Phase III clinical study evaluating sacituzumab tirumotecan (sac-TMT) in combination with MSD's pembrolizumab (Keytruda) has met primary endpoints for first-line treatment of PD-L1-negative, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). This represents the world's first Phase III success of an antibody-drug conjugate (ADC) combined with an immune checkpoint inhibitor in this challenging patient population.","og_url":"https:\/\/flcube.com\/?p=70015","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-15T04:23:05+00:00","article_modified_time":"2026-07-15T04:23:06+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70015#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70015"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kelun-Biotech&#8217;s Sacituzumab Tirumotecan Achieves World&#8217;s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC","datePublished":"2026-07-15T04:23:05+00:00","dateModified":"2026-07-15T04:23:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70015"},"wordCount":395,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial results","HKG: 6990","Kelun-Biotech Biopharmaceutical","Merck","Merck Sharp &amp; Dohme","MSD"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70015#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70015","url":"https:\/\/flcube.com\/?p=70015","name":"Kelun-Biotech's Sacituzumab Tirumotecan Achieves World's First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-15T04:23:05+00:00","dateModified":"2026-07-15T04:23:06+00:00","description":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.\u00a0(HKG: 6990) announced that its Phase III clinical study evaluating sacituzumab tirumotecan (sac-TMT) in combination with MSD's pembrolizumab (Keytruda) has met primary endpoints for first-line treatment of PD-L1-negative, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). This represents the world's first Phase III success of an antibody-drug conjugate (ADC) combined with an immune checkpoint inhibitor in this challenging patient population.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70015#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70015"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70015#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kelun-Biotech&#8217;s Sacituzumab Tirumotecan Achieves World&#8217;s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70015"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70015\/revisions"}],"predecessor-version":[{"id":70018,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70015\/revisions\/70018"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70015"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70015"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}